First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma von Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

Volltext

PB2198: TRIAL IN PROGRESS: AN OPEN‐LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL‐895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS)... von Palandri, Francesca, Gröpper, Stefanie, Loschi, Michael, Bellesso, Marcelo, Grosicki, Sebastian, Giraldo, Pilar, Harrison, Claire, Clevenger, Tracy, Stuart, Nikki, Qamoos, Hope, Vosganian, Gregory, Rothbaum, Wayne P., Verstovsek, Srdan, Vachhani, Pankit

Volltext

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) von Powderly, John, Spira, Alexander, Kondo, Shunsuke, Doi, Toshihiko, Luke, Jason J., Rasco, Drew, Gao, Bo, Tanner, Minna, Cassier, Philippe A., Gazzah, Anas, Italiano, Antoine, Tosi, Diego, Afar, Daniel E., Parikh, Apurvasena, Engelhardt, Benjamin, Englert, Stefan, Lambert, Stacie L., Kasichayanula, Sreeneeranj, Mensing, Sven, Menon, Rajeev, Vosganian, Gregory, Tolcher, Anthony

Volltext

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer von Calvo, Emiliano, Spira, Alexander, Miguel, María de, Kondo, Shunsuke, Gazzah, Anas, Millward, Michael, Prenen, Hans, Rottey, Sylvie, Warburton, Lydia, Alanko, Tuomo, Cassier, Philippe A., Yoh, Kiyotaka, Italiano, Antoine, Moreno, Victor, Peltola, Katriina, Seto, Takashi, Toyozawa, Ryo, Afar, Daniel E., Englert, Stefan, Komarnitsky, Philip, Lambert, Stacie, Parikh, Apurvasena, Vosganian, Gregory, Gao, Bo

Volltext

Immunologic Effects of an Orally Available BRAFV600E Inhibitor in BRAF Wild-type Murine Models von VOSGANIAN, Gregory S, BOS, Rinke, SHERMAN, Linda A

Volltext

Effects of long-term cryopreservation on peripheral blood progenitor cells von Vosganian, Gregory S, Waalen, Jill, Kim, Kevin, Jhatakia, Sejal, Schram, Ethan, Lee, Tracey, Riddell, Dan, Mason, James R

Volltext

Primary intraocular lymphoma: a review von Vosganian, Gregory S., Boisot, Saskia, Hartmann, Kathrin I., Freeman, William R., Sharpe, Robert W., Tripuraneni, Prabhakar, Saven, Alan

Volltext

Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial von Lambert, Stacie, Zhang, Chun, Englert, Stefan, Guo, Claire, Turan, Tolga, Tribouley, Catherine, Masica, David, McLaughlin, Robert T., Vosganian, Gregory S., Afar, Daniel E.

Volltext

Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors von Powderly, John, Shimizu, Toshio, LoRusso, Patricia, Razak, Albiruni, Miller, Kathy, Balar, Arjun, Bruix, Jordi, Michel, Loren, Blaney, Martha, Guan, Xiaowen, Lacy, Susan, Lally, Satwant, Lambert, Stacie, Leibman, Rachel, Vosganian, Gregory, Golan, Talia, Tolcher, Anthony

Volltext

Immunologic Effects of An Oral BRAF Inhibitor in a BRAF Wild-Type Murine Model von Vosganian, Gregory S., Bos, Rinke, Sherman, Linda

Volltext

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer von Bendell, Johanna C., Patel, Manish R., Brachmann, Carrie Baker, Huang, Xi, Maltzman, Julia D., Smith, Victoria, Vosganian, Gregory Sumpao, Wainberg, Zev A., Starodub, Alexander

Volltext

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - R... von Flinn, Ian W., Brunvand, Mark, Choi, Michael Y., Dyer, Martin J.S., Gribben, John, Hillmen, Peter, Jones, Jeffrey, Li, Yan, Mobasher, Mehrdad, Vosganian, Gregory, Kipps, Thomas J.

Volltext

Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leu... von Flinn, Ian, Brunvand, Mark, Dyer, Martin JS, Hillman, Peter, Jones, Jeffrey, Lymp, James, Elhamy, Mostafa, Vosganian, Gregory, Huang, Jane, Kipps, Thomas J.

Volltext

Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymp... von Salles, Gilles Andre, Boyd, Thomas E, Morschhauser, Franck, Wendtner, Clemens-Martin, Lymp, James, Hilger, James, Vosganian, Gregory, Huang, Jane, Stilgenbauer, Stephan

Volltext

Brief Communication: Immunologic Effects of an Orally Available BRAFV600E Inhibitor in BRAF Wild-Type Murine Models von Vosganian, Gregory S., Bos, Rinke, Sherman, Linda A.

Volltext

Differential frequency of breast cancer molecular profiling by socioeconomic status in San Diego, California von Vosganian, Gregory Sumpao, Rosenberg, Joshua Daniel, Verman, Radha, Waalen, Jill, Mason, James R.

Volltext

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer von Calvo, Emiliano, Spira, Alexander, Miguel, María de, Kondo, Shunsuke, Gazzah, Anas, Millward, Michael, Prenen, Hans, Rottey, Sylvie, Warburton, Lydia, Alanko, Tuomo, Cassier, Philippe A, Yoh, Kiyotaka, Italiano, Antoine, Moreno, Victor, Peltola, Katriina, Seto, Takashi, Toyozawa, Ryo, Afar, Daniel E, Englert, Stefan, Komarnitsky, Philip, Lambert, Stacie, Parikh, Apurvasena, Vosganian, Gregory, Gao, Bo

Volltext